Pterostilbene vs Resveratrol: Which Stilbene Is Better for Longevity?

At a Glance

Resveratrol spent two decades as the longevity world’s most celebrated molecule — the active compound allegedly explaining the French Paradox and the subject of landmark sirtuin research. Then pterostilbene quietly stepped out of the shadows.

Structurally, pterostilbene is resveratrol’s methylated cousin: same stilbene backbone, two additional methyl groups at the 3 and 5 positions. Those two small chemical modifications produce outsized pharmacokinetic advantages. The result is a compound that is absorbed more efficiently, distributed more broadly into tissues, and cleared more slowly from the bloodstream than its famous predecessor.

In my integrative practice, I see patients who have been taking resveratrol for years based on the early SIRT1 literature and want to know whether they should switch. The answer, like most things in functional medicine, is nuanced. This article walks through the biochemistry, the comparative evidence, and the clinical protocol I use to help patients make an informed decision.

The Resveratrol Story: SIRT1, Sirtuins, and the Red Wine Hypothesis

Resveratrol (3,5,4′-trihydroxystilbene) first attracted serious longevity interest in 2003 when David Sinclair’s lab published a landmark Nature paper demonstrating that it activated Sir2, the yeast homolog of SIRT1, and extended yeast lifespan by 70%.¹ SIRT1 is a NAD⁺-dependent deacetylase — it removes acetyl groups from histones and transcription factors, influencing gene expression patterns associated with metabolic efficiency and cellular stress resistance.

The excitement intensified when resveratrol was shown in rodent studies to mimic some effects of caloric restriction: improved insulin sensitivity, reduced adiposity, and enhanced mitochondrial biogenesis via PGC-1α activation. In obese mice, high-dose resveratrol extended median lifespan and significantly delayed age-related metabolic decline.²

Human trials, however, have been more equivocal. The primary challenge is pharmacokinetics. After oral ingestion, resveratrol is rapidly metabolized in the gut and liver — primarily into resveratrol sulfates and glucuronides — before it can reach target tissues. Peak plasma concentrations following a 500 mg oral dose are reached in 30–60 minutes, but the free (unconjugated) fraction is low, and the plasma half-life of unchanged resveratrol is typically under 15 minutes.

This creates a translation problem: the cellular concentrations used in in vitro studies are difficult to achieve in peripheral tissues with oral dosing. Despite this, meta-analyses of human trials have shown that resveratrol supplementation at 150–500 mg/day produces modest but measurable improvements in fasting glucose, blood pressure, LDL cholesterol, and inflammatory markers including CRP and TNF-α.³

Pterostilbene: The Methylated Upgrade

Pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene) is found in highest concentrations in blueberries, but also in Pterocarpus marsupium (Indian Kino Tree) bark — used for centuries in Ayurvedic medicine for blood sugar management. The two methyl ether groups on the A-ring dramatically alter the molecule’s behavior in the body.

Bioavailability. The methyl groups increase lipophilicity, reducing first-pass metabolism and improving intestinal absorption. A pharmacokinetic study in rats found that pterostilbene had approximately 80% oral bioavailability compared to roughly 20% for resveratrol.⁴ While direct head-to-head human pharmacokinetic data is limited, the available evidence strongly supports superior absorption for pterostilbene.

Half-life and tissue distribution. The elimination half-life of pterostilbene in humans is approximately 105 minutes — roughly 7–8× longer than resveratrol. This means fewer peaks and troughs in plasma concentration with once-daily dosing, and more sustained occupancy of molecular targets. The increased lipophilicity also facilitates better blood-brain barrier penetration, making pterostilbene particularly relevant for neuroprotective applications.

Potency. Despite being structurally similar, the two compounds are not pharmacologically identical. In cellular assays, pterostilbene demonstrates equivalent or greater SIRT1-activating potency relative to resveratrol on a molar basis. Pterostilbene also shows stronger activation of the AMPK pathway — a key energy-sensing kinase that suppresses mTOR and promotes autophagy — which may explain some of its anti-diabetic effects observed in preclinical models.⁵

Head-to-Head: What the Clinical Evidence Actually Shows

Resveratrol Human Trials

The human trial database for resveratrol is substantially larger, with more than 50 randomized controlled trials published across conditions ranging from type 2 diabetes to cardiovascular disease to Alzheimer’s disease.

Key findings from well-powered trials:

• A 2018 meta-analysis of 21 RCTs (n=1,228) found that resveratrol supplementation significantly reduced fasting blood glucose, insulin, and HOMA-IR in participants with metabolic syndrome or diabetes.³
• Trials in heart failure patients have shown improvements in systolic function and reductions in NT-proBNP with 100–500 mg/day.
• In Alzheimer’s disease, a phase 2 trial (n=119) showed resveratrol (1,000 mg twice daily) stabilized CSF Aβ40 levels over 52 weeks, though cognitive outcomes were unchanged.
• A consistent finding across trials: doses above 1,000 mg/day frequently cause GI adverse effects including nausea, diarrhea, and abdominal discomfort.

Pterostilbene Human Trials

Fewer human trials exist, but the available data is encouraging. A double-blind, placebo-controlled trial (n=80) examining pterostilbene for blood pressure found that 100 mg twice daily significantly reduced systolic and diastolic blood pressure over 6–8 weeks, with a modest LDL-raising effect at the higher dose.⁶

In a study examining cognitive effects in older adults, pterostilbene (50 mg and 100 mg twice daily) combined with grape seed extract improved subjective memory and certain cognitive performance measures compared to placebo over 90 days.

Importantly, the LDL increase observed with 200 mg/day pterostilbene has been noted in multiple analyses. While the mechanism is not fully established, it appears dose-dependent and less common at 100 mg/day or below. Patients with existing dyslipidemia should monitor lipids when using higher pterostilbene doses.

Molecular Targets Beyond SIRT1

Both compounds exert effects across multiple longevity-relevant pathways, though with different selectivity profiles.

SIRT1 and NAD⁺ metabolism. Both activate SIRT1 directly and may potentiate NAD⁺-dependent signaling. Resveratrol also inhibits cAMP phosphodiesterases (PDEs), which raises cAMP and activates AMPK indirectly — a mechanism not fully replicated by pterostilbene.

NF-κB inhibition. Both compounds suppress NF-κB-driven inflammation. This translates into reduced production of IL-6, TNF-α, and COX-2 in preclinical and some clinical models, making them relevant to the chronic low-grade inflammation (“inflammaging”) that underlies most age-related disease.

Nrf2 activation. Pterostilbene is a potent Nrf2 activator, upregulating antioxidant response elements including heme oxygenase-1 (HO-1) and glutathione synthesis. This pathway is important for mitochondrial protection and detoxification — particularly relevant for patients with heavy metal burden or environmental toxin exposure that I commonly see in my practice.

Senolytic activity. At higher concentrations, both compounds have shown the ability to selectively induce apoptosis in senescent cells — the “zombie cells” that drive tissue dysfunction with aging. The combined SIRT1/NF-κB/Nrf2 action may contribute to this senolytic profile, though neither compound is a first-line senolytic in clinical protocols.

Dr. Douwes’s Clinical Approach to Stilbene Supplementation

In practice, I rarely frame this as an either/or decision. The two compounds have complementary pharmacology: resveratrol’s PDE inhibition provides a cAMP-mediated mechanism that pterostilbene does not reliably replicate, while pterostilbene’s superior bioavailability and CNS penetration fill gaps that resveratrol’s rapid metabolism leaves open.

For most longevity patients, I recommend a stack of:

• Pterostilbene: 50–100 mg twice daily
• Resveratrol: 150–250 mg once daily (morning)

This keeps both compounds within the dose range where the evidence is strongest and adverse effects are minimal, while exploiting their distinct mechanistic profiles.

For patients with significant neuroinflammation or cognitive concerns (post-COVID brain fog, early neurodegeneration, Lyme neuroborreliosis), I prioritize pterostilbene at 100 mg twice daily given its superior CNS bioavailability.

For metabolic syndrome or insulin resistance, both compounds are relevant, but I often add berberine to the regimen given its more robust RCT evidence for glucose regulation, using the stilbenes as supporting anti-inflammatory agents rather than primary metabolic interventions.

Timing considerations: Both are fat-soluble and should be taken with a meal containing dietary fat to optimize absorption. Taking them alongside a NAD⁺ precursor (NMN or NR) makes mechanistic sense given the shared SIRT1 pathway.

Key caution: At doses above 200 mg/day, pterostilbene has shown LDL-raising effects in some individuals. I monitor a full lipid panel including LDL particle size (not just LDL-C) at 3 months for patients starting higher-dose pterostilbene, particularly those with cardiovascular risk factors.

Which Should You Choose?

The short answer: if forced to choose one, pterostilbene’s pharmacokinetic advantages make it the higher-value investment per milligram. But the body of evidence — particularly for cardiovascular and metabolic outcomes — remains substantially larger for resveratrol.

For patients willing to take a two-compound approach, the combination at moderate doses gives the best of both: breadth of evidence from the resveratrol literature and the pharmacokinetic reliability of pterostilbene.

As with any longevity-focused supplement, context matters enormously. These compounds are adjuncts to — not substitutes for — adequate sleep, structured exercise, a whole-food dietary pattern, and management of underlying metabolic or infectious drivers of inflammation. Used thoughtfully within that framework, stilbenes represent one of the more evidence-supported additions to a functional longevity stack.

Related Articles

• Resveratrol: Sirtuin Activation and the Case for Supplementation
• Senolytics: The Science of Clearing Zombie Cells
• Quercetin vs Fisetin: Which Senolytic Polyphenol Wins?
• NAD+ IV vs Oral NMN: What Dr. Douwes Recommends
• The Anti-Aging Supplement Stack: A Physician’s Guide

References

1. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196. PMID: 12939617
2. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–342. PMID: 17086191
3. Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014;99(6):1510–1519. PMID: 24695889
4. Remsberg CM, Yáñez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res. 2008;22(2):169–179. PMID: 17726731
5. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32(7):537–541. PMID: 22901562
6. Riche DM, Riche KD, Blackshear CT, et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:459165. PMID: 24790644
7. McCormack D, McFadden D. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482. PMID: 23738047